Search

everythinglearnresearchcommunity

for

Search:↓

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

HPV8 causes skin cancer by expanding specific skin stem cells.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

Keratin mutations cause skin diseases and could lead to new treatments.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.

Overexpressing PKCepsilon in mice reduces papillomas but increases carcinomas.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.

JAK inhibitors show promise for treating various skin diseases.

New treatments for cancer and skin disorders show promise in disrupting harmful cell interactions and promoting hair growth.

JAK/STAT1 pathway causes hair loss during chemotherapy by reducing Shh in hair follicles.

QLT0267 stops hair follicle cell growth and movement.

Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.

Blocking YAP/TAZ could be a new way to treat skin cancer.

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

Ruxolitinib helped a patient with alopecia areata regrow hair.

miR-22 helps skin cancer grow and spread by activating specific cell signals.

CENPV, a new partner of CYLD, helps regulate ciliary acetylated tubulin and is overexpressed in certain skin tumors.

New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Keratins 8 and 14 can help identify and diagnose benign skin tumors.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Activating certain cells in hair follicles can prevent hair loss caused by cancer treatments.

JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.